Center for Speech & Language Recovery
Clinical Trials

You are here

rTMS or tDCS and Speech Therapy in Sub-Acute Stroke

CLINICAL TRIAL: 
Complete
September 1, 2015 to September 1, 2017
Trial Identifier: 
NCT02020421
Published Clinical Trial: 
clinicaltrials.gov

The goal of this multinational clinical trial is to determine whether navigation guided 1 Hz rTMS (or cathodal tDCS) targeting the non-lesioned hemisphere Broca’s area homologue in patients with post-stroke aphasia, has a beneficial effect when combined with inpatient speech therapy.

Eligibility

Age Range: 
50 Years to 85 Years
Gender: 
Both (Male and Female)
Healthy Volunteers: 
No
Inclusion Criteria: 
  • Ischemic stroke in the left MCA territory
  • Between 5 and 30 days post stroke
  • Right-handedness
  • English, French or German as language of daily use
  • Score below the lower limit of the norm on at least one of the primary outcome measures
Exclusion Criteria: 
  • Prior symptomatic ischemic or hemorrhagic stroke
  • Severe comprehension deficit that may compromise informed consent or understanding of instructions
  • Contraindications to MRI and/or TMS/tDCS
  • Neurodegenerative or psychiatric disease
  • Epilepsy or EEG-documented epileptic discharges
  • Chronic renal or liver failure
  • Life-threatening diseases
  • Auditory or visual deficits that cannot be corrected and might impair testing

Sponsor

Northstar Trial

Study Locations

Burke Medical Research Institute
785 Mamaroneck Avenue
White Plains, NY 10573

Associated